Grifols/$GRFS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Grifols
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
- Ticker
- $GRFS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 25,258
- Headquarters
- Barcelona, Spain
- Website
- www.grifols.com
Grifols Metrics
BasicAdvanced
$7.3B
11.52
$0.74
1.19
$0.09
0.22%
Price and volume
Market cap
$7.3B
Beta
1.19
52-week high
$9.90
52-week low
$6.96
Average daily volume
744K
Dividend rate
$0.09
Financial strength
Current ratio
2.373
Quick ratio
0.686
Long term debt to equity
1.104
Total debt to equity
1.172
Dividend payout ratio (TTM)
28.32%
Interest coverage (TTM)
2.24%
Profitability
EBITDA (TTM)
1,840.931
Gross margin (TTM)
37.40%
Net profit margin (TTM)
6.09%
Operating margin (TTM)
17.60%
Effective tax rate (TTM)
19.16%
Revenue per employee (TTM)
$324,490
Management effectiveness
Return on assets (TTM)
4.10%
Return on equity (TTM)
6.93%
Valuation
Price to earnings (TTM)
11.525
Price to revenue (TTM)
0.701
Price to book
1.18
Price to tangible book (TTM)
-1.27
Price to free cash flow (TTM)
8.104
Free cash flow yield (TTM)
12.34%
Free cash flow per share (TTM)
1.05
Dividend yield (TTM)
1.01%
Forward dividend yield
0.22%
Growth
Revenue change (TTM)
-0.33%
Earnings per share change (TTM)
46.08%
3-year revenue growth (CAGR)
4.63%
10-year revenue growth (CAGR)
6.41%
3-year earnings per share growth (CAGR)
329.35%
10-year earnings per share growth (CAGR)
-1.77%
What the Analysts think about Grifols
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Analyst projections of the future price of Grifols stock.
Bulls say / Bears say
H1 2026 revenue rose 2.6% at constant currency, while immunoglobulins grew 12.8% and net profit rose 28.7%. Continued demand for its core plasma therapies is supporting growth and earnings. (Grifols)
Grifols plans to invest a further €180 million in Egypt, targeting annual plasma collection capacity of three million litres by 2029. If delivered, this could diversify supply and improve sourcing economics. (Grifols)
Grifols refinanced all 2027 debt maturities and redeemed €500 million of 2030 bonds, leaving no significant maturities until Q4 2028; H1 liquidity was €2.03 billion. This eases near-term refinancing pressure. (Grifols)
Net leverage was still 4.2x at H1, despite the refinancing and €2.03 billion of liquidity. The debt burden leaves little room for operational setbacks and makes sustained cash generation important. (Grifols)
Health Canada suspended the licence at Grifols’ Winnipeg plasma site after finding deficiencies in its quality management system, while the company had paused collections across its Canadian centres. The regulatory issues could delay a restart and disrupt its Canadian supply plans. (Reuters, CBC News)
Albumin revenue fell by more than 14% in H1 at constant exchange rates, amid pricing pressure in China. Continued weakness could offset growth in immunoglobulins. (Iber Empresa)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
Grifols Financial Performance
Revenues and expenses
Grifols Earnings Performance
Company profitability
Upcoming events
No upcoming events
Grifols News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.